1 / 14

Financial incentives for chlamydia testing: A review of the literature

Financial incentives for chlamydia testing: A review of the literature. Darko Molinar and Anthony Nardone Office Sexual Health Promotion, HIV/STI Department. Background. Several reviews (incl. Kane et al. 2004;Sutherland et al. 2008) concluded patient-targeted economic incentives are:

guy
Download Presentation

Financial incentives for chlamydia testing: A review of the literature

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Financial incentives for chlamydia testing: A review of the literature Darko Molinar and Anthony Nardone Office Sexual Health Promotion, HIV/STI Department

  2. Background • Several reviews (incl. Kane et al. 2004;Sutherland et al. 2008) concluded patient-targeted economic incentives are: • Successful in effecting “simple behaviour” change • e.g. immunisation, treatment adherence, etc. • Less successful for “complex behaviour” change • e.g. smoking cessation, weight loss, increasing physical activity etc. • Increase participation rates but do not necessarily impact on the outcome of interest

  3. Background: NCSP & incentives • Variety of economic incentives used by some NCSP programme areas to increase chlamydia screening • e.g. Lottery (“Wee for a Wii”), £10 shopping vouchers etc • NCSP position statement (November 2008) • Incentives need to be proportionate (e.g. pens but not alcohol) • Justifiable under public scrutiny • NCSP/DH press statement (March 2009) • Evaluation of impact of using incentives • Literature review of available evidence

  4. Aims and objectives • Identify and summarise studies, where patient financial incentives have been employed to encourage chlamydia screening, in order to inform policy development. • Review literature for evidence of patient financial incentives to encourage uptake of chlamydia screening and other relevant sexual health initiatives; • Identify possible unintended consequences of financial incentives to encourage uptake of STI screening.

  5. Methods • Review of English language peer reviewed literature (April 1987-March 2009) • All study types included • Various combinations of search terms used: • Electronic databases (PubMeD; EMBase; PsychInfo; Cochrane) • Internet search engine (Google) • Manual search of conference abstracts (2003-2008): • International Society for Sexually Transmitted Diseases Research; British Association for Sexual Health and HIV; NCSP • Citation search of selected references

  6. Results • 5 studies of chlamydia screening • 1 study of postal chlamydia screening uptake • 2 studies of repeat testing following diagnosis with chlamydia (Ct) or gonorrhoea (Gc) • 2 studies of participation in sexual health surveys, with chlamydia testing offered • 5 studies of other sexual health initiatives • 2 studies of attendance at sexual health workshops (Carey et al. 2005; Kamb et al. 1998;) • 1 study of attendance for test-of-cure for Gc (Chacko et al. 1987) • 1 qualitative study - perspectives of high risk youth on chlamydia screening (Blake et al. 2003)

  7. Postal Ct screening uptake ClaSS study - Low et al. 2007 • Cross-sectional community based prevalence study of chlamydia • Self-test kits posted to 16-39 yr olds on GP clinic lists • 27 surgeries in Bristol and Birmingham, UK, in 2001/2 • Randomised Control Trial (RCT): • Sample of young people recruited from a single GP clinic (n=836) • Randomly allocated to either £10 voucher or no incentive • Incentives had no significant effect on uptake: • uptake in incentive arm was 73/418 vs. 69/418 in the control arm

  8. Repeat testing • Kissinger et al. 2000 • Time-series in an urban STD clinic in USA (n=962) • Follow-up of 14-34 yr old women diagnosed with Ct • $20 to return for 1 and 4 month follow-up • Incentives found to increase return rate (adjusted OR 1.9) • Malotte et al. 2004; Gift et al. 2005 • RCT 14-30 yr olds diagnosed with Ct/Gc (n=421) in 2 STD clinics in USA • Allocated to one of three possible interventions to return for follow-up appointment within 3-4 months: 1. Verbal recommendation given at diagnosis (standard) 2. Standard and financial incentive ($20) 3. Standard, motivational interview and telephone reminder at month 3 • Follow up rates highest with telephone reminder. Financial incentive performed no better than standard

  9. Sexual health surveys • Erens et al. 2005 (NATSAL*): • In pilot stage individuals were randomised to being offered £5 voucher or £5 charity donation to participate in study • Response rate when given £5 voucher > 1997 study when no incentive offered, but charity donation had no effect • Incentives used in subsequent NATSAL survey in 2001 • Eggleston et al. 2005 • Case series with no control group in Baltimore USA (n=100) • $10 offered for telephone survey of sexual health in 18-35 yr olds • $40 offered in addition for returned urine samples. • 86% mailed back urine sample * National Survey of Sexual Attitudes and Lifestyles

  10. Discussion Population groups • Incentives have often been directed at disadvantaged populations (Kane et al 2004) • Ethical argument that incentives should be focussed on disadvantaged populations (Cookson 2008) • NCSP screening provision and coverage currently higher in more socio-economically deprived areas Size and type of incentive • Kane et al. 2004: • Incentives relevant to behaviour change sought have been shown to be more effective than more diffuse incentives • Cash/coupons have greater effect than lottery/gifts for simple behaviour change • Malotte et al. 1998: higher cash value resulted in higher return rates for TB skin tests among injecting drug users

  11. Discussion (2) Timing of incentive • Longer time periods between health seeking and payment associated with poorer participation (Malotte et al. 2004) Sustained behaviour change • Incentives shown to increase participation in programmes, but little evidence of impact on long-term behaviour change: • e.g. Kamb et al 1998: $15 increased attendance at STI risk-reduction sessions (55% v 37%) but post-study STD rate same at 6, 12 and 24 months • Ct screening can be seen as a simple behaviour change but: • To achieve the aims of NCSP will require young people to test regularly between 16 and 24 years of age • Incentives may inhibit intrinsic motivation of individuals young people to screen regularly • Individuals should be aware that incentives are only a temporary support to help them achieve their personal health goals (Kane et al 2004)

  12. Discussion (3) Ethical considerations (Draper et al. 2009) • Incentive should not be coercive • The level of coercion will depend not only on the size of the incentive but also on the characteristics of the recipient • Any incentives should avoid purposefully exploiting a potential participant’s weakness or vulnerability, such as financial need Unintended consequences • As the NCSP targets 15-24 yr olds, payment for Ct screening could be misconstrued as encouragement for starting/increasing sexual activity at a young age • Systems to detect any possible deception to obtain the reward

  13. Conclusions • Limited evidence base available • 1 RCT directly relevant to NCSP • 9 studies peripheral to chlamydia screening • Many questions remain unanswered • Need for strong evaluation of current initiatives to inform policy development • Database of different financial incentives used • PCT information reported by evaluation forms • Further analysis and evaluation through use of routine NCSP data: • Compare screening in programme areas (PA) using and not using incentives as well as within PA • User evaluation of incentives

  14. References • Cookson R. (2008) Should disadvantaged people be paid to take care of their health? Yes. BMJ337; 140 • Draper H et al. (2009) Offering payments, reimbursements and incentives to patients and family doctors to encourage participation in research. Fam Prac26(3):231-238. • Eggleston E et al. (2005) Monitoring STI prevalence using telephone surveys and mailed urine specimens: a pilot test. Sex Transm Inf 81:236-238 • Erens B et al. (2005)National survey of sexual attitudes and Lifestyles II: Technical report. • Gift TL et al (GCAP Study Group) (2005) Acost-effectiveness analysis of interventions to increase repeat testing in patients treated for gonorrhoea or chlamydia at public sexually transmitted disease clinics. Sex Trans Diseases32(9):542-549 • Jochelson K. (2007) Paying the patient – Improving health using financial incentives. King’s Fund. London • Kamb M et al. (1998) What about money? Effect of small monetary incentives on enrolment, retention and motivation to change behaviour in an HIV/STD prevention counselling intervention. Sex Trans Inf 74: 253-255 • Kane RL et al. (2004) A structured review of the effect of economic incentives on consumers’ Preventative behaviour. Am J Prev Med27(4): 327-352 • Kissinger P et al. (2000) The effect of modest monetary incentives on follow up rates in sexually transmitted disease studies. Int J STD & AIDS 11:27-30 • Low N et al. (2007) Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess11(8) • Malotte CK et al (1998) Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health88:792-796 • Malotte CK et al (GCAP Study Group) (2004) Comparison of methods to increase repeat testing in persons treated for gonorrhoea and/or chlamydia at public sexually transmitted disease clinics. Sex Trans Diseases31:637-642 • Stevens-Simon C et al. (1997) A randomized trial of the Dollar-a-Day Program. JAMA 277: 977-82 • Sutherland et al. (2008) Paying the patient: does it work? A review of patient targeted incentives. Health Foundation, London

More Related